Recently stock market analysts have updated their consensus ratings on shares of BioAmber Inc. (NYSE:BIOA).

Most recent broker ratings

03/10/2016 – BioAmber Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 5.5 price target on the stock.

01/05/2016 – H.C. Wainwright began new coverage on BioAmber Inc. giving the company a “buy” rating. They now have a USD 18 price target on the stock.

05/11/2015 – BioAmber Inc. was downgraded to “sell” by analysts at Zacks.

11/24/2014 – BioAmber Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 16 price target on the stock.

07/18/2014 – BioAmber Inc. had its “buy” rating reiterated by analysts at Societe Generale. They now have a USD 16 price target on the stock.

01/23/2014 – BioAmber Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 17 price target on the stock.

BioAmber Inc. has a 50 day moving average of 4.23 and a 200 day moving average of 5.40. The stock’s market capitalization is 79.64M, it has a 52-week low of 2.87 and a 52-week high of 9.09.

The share price of the company (NYSE:BIOA) was down -10.20%, with a high of 3.47 during the day and the volume of BioAmber Inc. shares traded was 100348.

View other investors thoughts on BioAmber Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.